Heather A. Wakelee, MD (Medical Oncology)

Department of Medical Oncology, Stanford Cancer Institute, Stanford, California.

Dr. Heather Wakelee is a Professor of Medicine in the Division of Oncology at Stanford University and is the faculty director of the Stanford Cancer Clinical Trials Office. She is a graduate of Princeton University and Johns Hopkins University School of Medicine and completed all post-graduate training at Stanford University.  Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and other thoracic malignancies and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others.  She is also involved in trials of adjuvant therapy, immunotherapy and anti-angiogenesis agents in addition to collaborations with colleagues focused in biomarkers and others focused in population science research.  Dr. Wakelee is active in multiple national and international lung cancer research organizations including serving as a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC), co-chair of the thoracic committee, executive committee member, and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and Fellow of the American Society of Clinical Oncology (FASCO).  Her work in immunotherapy of thoracic malignancies includes participation in multiple phase III trials of PD-(L)1 checkpoint inhibitors in advanced stage NSCLC and more recently involvement on steering committees for two phase III international trials exploring immune checkpoint inhibitors in the peri-operative period.  She actively collaborates with many basic scientists at Stanford University seeking to better understand molecular and other biomarkers of immune response.